Publications
Spotlight Publication
Balstilimab (PD-1 Antagonist), Botensilimab (Fc-Enhanced CTLA-4 Antagonist)
European Society for Medical Oncology
Sep 13
- Sep 17, 2024
Updated efficacy and safety of botensilimab plus balstilimab in patients with refractory metastatic sarcoma from an expanded phase 1 study
Wilky, et al.
Filter by
Zalifrelimab (CTLA-4 Antagonist)
European Society for Medical Oncology (ESMO) Virtual
Sep 19
- Sep 21, 2020
Balstilimab (anti-PD-1) Alone and in Combination with Zalifrelimab (anti-CTLA-4)for Recurrent/Metastatic (R/M) Cervical Cancer (CC) Preliminary Results of Two Independent Ph2 Trials.
O’Malley, et al.
Zalifrelimab (CTLA-4 Antagonist)
Society for Immunotherapy of Cancer (SITC)
Nov 9
- Nov 14, 2020
Single-agent Zalifrelimab (anti-CTLA-4) Shows Clinical Benefit in Rare Tumors – Case Reports from a Phase 2 Study (NCT02694822).
Perez, et al.
Zalifrelimab (CTLA-4 Antagonist)
Society for Immunotherapy of Cancer (SITC)
Nov 9
- Nov 14, 2020
Pseudoprogression (PSP) Patterns: Analysis from 2 Independent Phase-2 Studies with Immunotherapy for Recurrent Cervical Cancer.
O’Malley, et al.
Zalifrelimab (CTLA-4 Antagonist)
European Society for Medical Oncology (ESMO) Virtual
Sep 16
- Sep 21, 2021
Balstilimab Alone or in Combination with Zalifrelimab as Second-line Treatment for Patients with Previously Treated Recurrent/metastatic Cervical Cancer: a Randomized, Placebo-Controlled Phase II Trial (RaPiDS/GOG-3028).
Randall, et al.
Zalifrelimab (CTLA-4 Antagonist)
European Society for Medical Oncology (ESMO) Virtual
Sep 16
- Sep 21, 2021
Balstilimab (anti-PD-1) in Combination with Zalifrelimab (anti-CTLA-4): Final Results from a Phase 2 Study in Patients (pts) with Recurrent/metastatic (R/M) Cervical Cancer (CC).
O’Malley, et al.
VISION
Society for Immunotherapy of Cancer (SITC)
Nov 6
- Nov 10, 2019
Driving T cell Dysfunction in Vitro for Rational Immunotherapy Design.
Joyce, et al.
VISION
AI Powered Drug Discovery and Manufacturing (AIDM)
Feb 27
- Feb 28, 2020
Using Big Data and Machine Learning to Understand T cell Dysfunction in Human Tumors.
Pabla, et al.
VISION
Society for Immunotherapy of Cancer (SITC)
Nov 9
- Nov 14, 2020
Beyond PD-L1: novel PD-1 biomarkers identified by driving T cell dysfunction in vitro.
Pabla, et al.
QS-21 STIMULON™ Adjuvant
The Journal of Immunology
Jan 15, 1991
Separation and Characterization of Saponins With Adjuvant Activity From Quillaja Saponaria Molina Cortex.
Kensil, CR.
QS-21 STIMULON™ Adjuvant
The Journal of Immunology
Apr 15, 1992
Saponin Adjuvant Induction of Ovalbumin-Specific CD8+ Cytotoxic T Lymphocyte Responses.
Newman, et al.
QS-21 STIMULON™ Adjuvant
Critical Reviews in Therapeutic Drug Carrier Systems
Jan 1, 1996
Saponins as Vaccine Adjuvants.
Kensil, CR.
QS-21 STIMULON™ Adjuvant
Cancer Research
Jul 1, 1995
GM2-KLH Conjugate Vaccine: Increased Immunogenicity in Melanoma Patients After Administration With Immunological Adjuvant QS-21.
Helling, et al.